Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-811 first-line HER2-positive advanced gastric/GEJ adenocarcinoma trial
MOH_2018-08-01_002446Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Pembrolizumab + trastuzumab + chemotherapy with Placebo + trastuzumab + chemotherapy (2 arms). Started Jun 2018; status: active, not recruiting.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on MOH_2018-08-01_002446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-08-01_002446.